Sagar Patel presents the REVELUTION trial comparing leuprolide versus relugolix effects on coronary plaque progression in 94 men with non-metastatic prostate cancer receiving pelvic radiotherapy.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Immunohistochemical Expression of Nectin-4 and Potential Implications for Enfortumab Vedotin Therapy in Germ Cell Tumors of the Testis: A Preliminary Study - Beyond the Abstract ...

The Role of Early, Multi-Modal Genomic Testing in Prostate Cancer ManagementSent on 12 January 2026 Prostate Cancer DailySent on 12 January 2026 Prostate Cancer DailySent on 09 January 2026 Why Timing ...

Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...

Relationship Between the Frequency of Electrocautery of Hunner Lesions and Changes in Bladder Capacity in Patients with Hunner Type Interstitial Cystitis - Beyond the Abstract ...

Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie's Disease Infiltrates the Tunica Albuginea - Beyond the Abstract ...

SUO 2025 BRCA-mutated metastatic castration-resistant prostate cancer, results from the TRITON3 study, rucaparib in BRCA-mutated mCRPC.

ASCO 2025 overall survival analysis of enzalutamide plus androgen-deprivation therapy (ADT), metastatic hormone-sensitive prostate cancer (mHSPC), ARCHES study.

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13 th and 16 th, 2024 was host to a session on future therapy targets ...

New Insights Beyond Established Norms: A Scoping Review of Genetic Testing for Infertile Men - Beyond the Abstract ...

ESMO 2025, PSMA-positive metastatic hormone-sensitive prostate cancer, [177Lu]Lu-PSMA-617, VISION trial, PSMAfore trial, PSMAddition trial, 68Ga-PSMA-11 PET/CT.